Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase - Wikidata - wikimedia - TriplyDB

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

http://www.wikidata.org/entity/Q28324076

about

Pathogenesis of human immunodeficiency virus infection Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1 3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture 5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors Mechanism of resistance of human immunodeficiency virus type 1 to 2',3'-dideoxyinosine Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analo pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

P2860

Q24634681-6755DCD4-0C03-4B78-9D71-DA94AF189DED Q24682078-4A337009-B7C2-4DE0-943B-B47934683EEB Q24684152-912949D0-98B3-4E6B-9BDA-8306B58E24C6 Q27729365-3885351B-2C8E-4EE9-8569-55FA7D015149 Q27764900-60F9DFAA-5D44-4B2B-8E8F-C7AEFCABFD80 Q28316118-DCC3B02A-B390-4C34-86EE-F18EE801C5A2 Q28316326-E89BF8D6-CE82-4CBC-9C93-228650FC18EE Q28316336-8D0CEDA4-074E-4B63-914B-9E6BC2C318F5 Q28326720-362AE4E5-4AEB-4092-8642-C297F479C881 Q28342653-28912969-DB39-4E71-8BFA-AD7B840898BD Q28342745-531831F1-F911-4706-90E8-F14769DA1345 Q28342752-E64E8F5B-8048-4595-8A5A-1D1805F73720 Q28343184-FFF15A77-873B-430D-B97E-2B50160789EE Q28343606-9970D413-5C27-4054-A09B-BB661F8CF59A Q28343615-7160213C-59CC-4DF5-914D-A82E1C4E0B5C Q28344137-65CF9B4B-2762-4648-9D87-70843D81AFFF Q28344355-B4D407A3-CC74-4A38-8A00-120D200E53CF Q28367386-9737E201-AB10-483C-B25D-B7B2EBCF4750 Q28367493-6D2D4055-B94E-4E53-8FAD-CD4F8811452D Q28367526-917AD5D4-C3AA-4A2F-B932-0DF97EA3F5A1 Q28367539-0C7363DB-7397-4B09-93D9-09AC2934D69C Q28367543-6B59160D-D462-4AEF-A803-AA0390BDB5BE Q28367547-BACD337B-B988-4BB4-AF42-9B785DF55C23 Q28367580-DB965622-61A0-49F5-AC94-6DAF71A226CA Q28367590-7CBA8804-3F3C-4C7B-AF6B-4140C1174F72 Q28367594-A841F325-F5C5-4BC5-ADEF-E50CE59FB495 Q28367605-B0EE4DB0-6144-4B7C-AF49-C918B6A2E7FB Q28367663-98C3004E-4D8D-4910-B938-D50601B35917 Q28368003-5BB13E68-BDFA-4209-B915-F703DB3FE183 Q28368026-EB484E84-0FB1-4AFF-914F-9731380A580D Q28368028-112C1A2C-4496-40A5-8A50-99A156801400 Q28368030-7DC944E5-EB17-4B23-8881-E61449F7F6DF Q28368032-8E6E7A95-C468-492D-8E9C-D2F811421380 Q28368041-3C5DD70C-441D-4F86-B041-246C8CD83A4B Q28368045-599AC40F-26F5-4A2B-BC4D-02F050D114AC Q28368048-DA198A98-6D41-47BD-B984-3D538FAF6AEF Q28368090-522CADCD-7865-4866-AAA5-9D7912628F83 Q28368263-9628EC7F-FA33-4943-886C-0444ECFF227C Q28368832-8D2F20D1-4039-40B7-A69A-A8984998C4DE Q28369516-2C4E6C0E-F8C8-40C6-B9A0-1791FF413D1D

P2860

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

http://www.wikidata.org/entity/Q28324076

description

1991 nî lūn-bûn

@nan

1991 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1991 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1991年の論文

@ja

1991年論文

@yue

1991年論文

@zh-hant

1991年論文

@zh-hk

1991年論文

@zh-mo

1991年論文

@zh-tw

1991年论文

@wuu

name

Resistance to ddI and sensitiv ...... in HIV-1 reverse transcriptase

@ast

Resistance to ddI and sensitiv ...... in HIV-1 reverse transcriptase

@en

Resistance to ddI and sensitiv ...... in HIV-1 reverse transcriptase

@nl

type

label

Resistance to ddI and sensitiv ...... in HIV-1 reverse transcriptase

@ast

Resistance to ddI and sensitiv ...... in HIV-1 reverse transcriptase

@en

Resistance to ddI and sensitiv ...... in HIV-1 reverse transcriptase

@nl

prefLabel

Resistance to ddI and sensitiv ...... in HIV-1 reverse transcriptase

@ast

Resistance to ddI and sensitiv ...... in HIV-1 reverse transcriptase

@en

Resistance to ddI and sensitiv ...... in HIV-1 reverse transcriptase

@nl

P1433

Q28324076-5EB0643B-D043-4148-B8CF-92FA22D01957

P1476

Q28324076-A6959012-29E8-4CE7-86E0-1D32B138796D

P2093

Q28324076-0322FDDA-C0AF-4A4E-857F-1E4F6097AB4E

Q28324076-36B10F35-BFCE-4EE1-B968-A437BCBEFA4F

Q28324076-7C1DD887-E300-416A-9522-7BA29B65BA90

Q28324076-8078EF4D-4E87-46D9-9F91-7C4DB0858A7A

Q28324076-8A3421E9-D5CC-4335-8DFD-D8E9E7988A73

Q28324076-B13A077F-FA3F-4CCD-9951-8D8B25EF57E2

Q28324076-D106E3FA-A302-4FDA-A604-75516DAB914D

Q28324076-FC8E95D9-CF57-4093-B2A7-2754B7AD7084

P304

Q28324076-174D5533-C856-4B3A-945E-85D9AAFED0E0

P31

Q28324076-BB13629D-2D37-48E6-9DE8-BF9E8DB77B02

P356

Q28324076-3AE30B01-88CB-4B58-A102-F6E38E8A8248

P407

Q28324076-44557C17-91C4-45CD-90E7-D87E5B5BB689

P433

Q28324076-C1D643C4-CBAE-43F7-B7B7-5604207A45B2

P478

Q28324076-F2336B67-25FA-4005-854B-E562693B3803

P50

Q28324076-99D9FA15-E4CD-4C1D-BC19-5690F0A80C33

P577

Q28324076-1FE4D72F-26BF-465B-9680-D87857A8B1C6

P698

Q28324076-05D4AD66-02F4-457B-89C6-0A5094D8C923

P356

SCIENCE.1716788

P1433

P1476

Resistance to ddI and sensitiv ...... in HIV-1 reverse transcriptase

@en

P2093

B A Larder

http://www.w3.org/2001/XMLSchema#string

C L Vavro

http://www.w3.org/2001/XMLSchema#string

D M King

http://www.w3.org/2001/XMLSchema#string

G Tudor-Williams

http://www.w3.org/2001/XMLSchema#string

J L Martin

http://www.w3.org/2001/XMLSchema#string

M C Bach

http://www.w3.org/2001/XMLSchema#string

M H St Clair

http://www.w3.org/2001/XMLSchema#string

S D Kemp

http://www.w3.org/2001/XMLSchema#string

P304

1557-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCIENCE.1716788

http://www.w3.org/2001/XMLSchema#string

P407

P433

5027

http://www.w3.org/2001/XMLSchema#string

P478

253

http://www.w3.org/2001/XMLSchema#string

P50

P577

1991-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1716788

http://www.w3.org/2001/XMLSchema#string